Overview

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Status:
Completed

Trial end date:
2017-10-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic for acute postoperative pain in pediatric subjects. This post marketing study was required by the FDA. Endo Pharmaceuticals Inc. no longer promotes opioids and no longer markets Opana® ER.

Phase:

Phase 3

Details

Lead Sponsor:

Endo Pharmaceuticals

Treatments:

Oxymorphone